Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000779

Drug Information
NameMefenamic acid    
Synonymsto_000071; Namphen; BSPBio_000207; M1782; Pinewood Brand of Mefenamic Acid; STK666691; Vialidon; SAM002554908; Parkemed; Ponmel; First Horizon Brand of Mefenamic Acid; Methenamic acid; Tanston; Apo-Mefenamic; AGN-1255; Mefac; 2-[(2,3-dimethylphenyl)amino]benzoic acid; Mycasaal; NCGC00022393-03; Contraflam; Benzoic acid, 2-((2,3-dimethylphenyl)amino)-; Pharmascience Brand of Mefenamic Acid; 2-(2,3-Xylidino)benzoic Acid; Ac. mefenamico; CID4044; Prestwick0_000054; EINECS 200-513-1; DB00784; PMS Mefenamic Acid; Prestwick3_000054; Mefacit; KBioSS_000654; NuMefenamic; Mefedolo; Pinalgesic; Ponalar; CI-473; Prestwick_506; Bafhameritin-M; MolPort-001-839-968; Acido mefenamico [INN-Spanish]; APS Brand of Mefenamic Acid; 2-(2,3-dimethylphenylamino)benzoic acid; CHEBI:129989; Acid, Mefenaminic; Ponstan; F0850-6853; Ponalgic; CAS-61-68-7; Anthranilic acid, N-2,3-xylyl-; Bonabol; NINDS_000298; BSPBio_002724; Acid, Mefenamic; Mephenamic acid; Spectrum2_001941; Prestwick2_000054; HMS1568K09; C02168; Ashbourne Brand of Mefenamic Acid; DivK1c_000298; Warner-Lambert Brand of Mefenamic Acid; Rolan; Nu-Mefenamic; CPD000058188; Mefanamic acid; Mefenamic acid [USAN:INN:BAN:JAN]; Nu Mefenamic; MLS000069709; A1077/0050549; SGCUT00005; HMS2090B07; Apo Mefenamic; N-(2,3-Dimethylphenyl)anthranilic acid; Anthranilic acid, N-(2,3-xylyl)-; Nu-Pharm Brand of Mefenamic Acid; Acido mefenamico; LS-20589; 2-(2,3-Dimethylanilino)benzoic acid; Pontal; AKOS001025551; NCGC00022393-04; N-2,3-Xylylanthranilic acid; IDI1_000298; Mephenaminic acid; Nu Pharm Brand of Mefenamic Acid; 2-((2,3-Dimethylphenyl)amino)benzoic acid; AC1Q2NNQ; 61-68-7; ID8; WLN: QVR BMR B1 C1; Bafameritin-M; Pfizer Brand of Mefenamic Acid; HMS1921D13; in-M; HSDB 3115; Ponstel (TN); BRD-K92778217-001-06-1; 2-Diphenylaminecarboxylic acid, 2',3'-dimethyl-; INF 3355; Chemidex Brand of Mefenamic Acid; BRN 2216243; Ponstan forte; Mefenaminsaeure; Mefenacid; Ac. mefenamico [Italian]; Acidum mefenamicum [INN-Latin]; Mefenamate; SPECTRUM1501103; KBio1_000298; KBio2_005790; I14-3644; Ponstyl; Godecke Brand of Mefenamic Acid; SMR000058188; INF-3355; KBio2_000654; Warner Lambert Brand of Mefenamic Acid; Lysalgo; CN 35355; KBio2_003222; UNII-367589PJ2C; CI 473; NCGC00016278-02; KBioGR_001730; Farmasierra Brand of Mefenamic Acid; PMS-Mefenamic Acid; Apotex Brand of Mefenamic Acid; NSC94437; Acide mefenamique [French]; D00151; M4267_SIGMA; InChI=1/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18; AC1L1HAE; Forte, Ponstan; Spectrum3_001082; AC-11160; N-(2,3-Xylyl)anthranilic acid; Rowa Brand of Mefenamic Acid; Oprea1_193889; Tamany Bonsan; Clonmel Brand of Mefenamic Acid; Acide mefenamique [INN-French]; Mefenamic acid (JP15/USP/INN); NCGC00016278-01; Mefenaminic Acid; SPBio_002128; Parke Davis Brand of Mefenamic Acid; NCGC00022393-05; D008528; Acide mefenamique; MLS001074162; ApoMefenamic; Ponstil; Elan Brand of Mefenamic Acid; Prestwick1_000054; mefenamic acid; NSC 94437; SMP2_000141; UNM000001233403; N-(2,3-Xylyl)-2-aminobenzoic acid; Ponsyl; Antigen Brand of Mefenamic Acid; CHEMBL686; HL 1; Coslan; CL 473; BPBio1_000229; HMS500O20; Mefenaminsaeure [German]; Benzoic acid, 2-[(2,3-dimethylphenyl)amino]-; CN-35355; SPBio_002001; Acidum mefenamicum; AB00052200; HMS2092B17; Spectrum5_001341; Ponstel; Spectrum4_001235; Benzoic acid, 2-(2,3-dimethylphenyl)amino-; KBio3_001944; Dysman; Spectrum_000174; Mefic    
Trade NamePonstel; Ponstan; Ponstal; Parkemed; Mafepain; Mephadolor; Meftal; Dyfenamic; Potarlon    
IndicationRheumatoid arthritis and osteoarthritisApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAnti-Inflammatory Agents    
CAS NumberCAS 61-68-7
PubChem Compound IDCID 4044.    
PubChem Substance IDSID 5243.    
SuperDrug ATC IDM01AG01;    
SuperDrug CAS ID000061687;    
TargetProstaglandin G/H synthase 2Inhibitor[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 015034 To Reference
Ref 2Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot Essent Fatty Acids. 1998 Jul;59(1):55-62. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543